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to 11%-16% of ezetimibe users, and 11%-19% of fibrate users. Nearly 4% of sta-
tin users augmented their regimen during the year, compared with 56%-61% of 
ezetimibe and 38%-51% of fibrate users. The proportion of patients not meeting the 
LDL-C target was 71% and 69% in the CV High Risk and CV Event History cohorts at 
index, respectively, and 65% for both at 12 months. Approximately 60% of diabetic 
patients of CV High Risk cohort did not meet LDL-C target at both index and 12 
months. ConClusions: Adherence to LMT after CV events was best for statins. 
Patients receiving fibrates or ezetimibe had higher rates of switching or augmenta-
tion. LDL-C goal attainment is low, representing a substantial unmet medical need.
MENTAL HEALTH – Clinical Outcomes Studies
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BACkground: Use of antipsychotic medications has been associated with 
increased risk of mortality; however, this association remains questionable given 
conflicting evidence in the literature. oBjeCtives: We conducted a systematic 
review and meta-analysis of observational studies to determine whether mortal-
ity was higher among antipsychotic (AP) users than AP nonusers. Methods: All 
articles published from 1970 to March 2015 were identified by comprehensively 
searching PubMed, MEDLINE, and EMBASE without language restrictions. Three 
reviewers independently extracted study characteristics and indicators of study 
quality. Random or fixed effects models were used to calculate pooled odd ratios 
(ORs) and evaluate heterogeneity (I2). results: We identified 17 (13 cohort and 4 
case-control) eligible studies with 123,116 deaths. Use of APs was associated with 
increased risk of all-cause mortality [OR 1.38, 95% confidence interval (CI) 1.12-1.69, 
I2 = 91.0%] and significantly higher risk of sudden cardiac death [OR 2.24, 95% CI 
1.71-2.92, I2 = 22.8%]. Compared to AP nonusers, the pooled OR for risk of death 
was 1.49 [95% CI 1.20-1.85, I2 = 84.3%] with first-generation antipsychotics (FGAs) 
exposure and 1.50 [95% CI 1.24-1.81, I2 = 89.3%] with second-generation antipsychot-
ics (SGAs) exposure. Subgroup analysis reported that current users of FGAs were at 
a higher risk of mortality [OR 1.78, 95% CI 1.67-1.90, I2 = 0%]. The pooled OR from 
current use of SGAs was 1.81 [95% CI 1.44-2.28, I2 = 85.3%]. Use of FGAs and SGAs 
among elderly patients was associated with a lower risk of death with a pooled OR 
of 1.13 [95% CI 0.69-1.85, I2 = 87.1%] and 1.36 [95% CI 0.90-2.05, I2 = 91.7%], respec-
tively. ConClusions: APs use, especially current users of SGAs, was associated 
with an increased risk of all-cause mortality. Exposure to APs was associated with 
a greater increase in sudden cardiac death. We did not observe a significant differ-
ence between subgroup analyses of FGAs and SGAs.
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oBjeCtives: There are several factors that affect the risk of developing dementia. 
Various studies have shown that defined diagnoses and medications increase or 
decrease dementia risk. But the relatively small numbers of dementia patients 
in some of these studies make the interpretation of their results difficult. The 
aim of this work was to estimate risk factors for dementia in German primary 
care patients. Methods: The case-control study included 11,956 primary care 
patients in the age group 70-90 years with first dementia diagnosis during the 
index period (01/2010-12/2014) (Disease Analyser, Germany). Furthermore, 11,956 
controls without any dementia diagnosis were included after individual match-
ing (1:1) to dementia cases on age, sex, type of health insurance and physician. 
The practice visit records were used to determine 10-year prior index continuous 
follow-up. Multivariate logistic regression models were fitted with dementia as 
dependent variable and the potential predictors. results: Mean age of patients 
and controls was 80.4 (SD: 5.3) years. 39.0% of them were male and 1.9% had a 
private health insurance. In multivariate regression model, the following variables 
were significantly related to an increased risk for dementia: diabetes (OR: 1.17; 
95% CI: 1.10-1.24), lipid metabolism (OR: 1.07; 1.00-1.14), stroke incl. TIA (OR: 1.68; 
1.57-1.80), Parkinson disease (OR: 1.89; 1.64-2.19), intracranial injury (OR: 1.30; 1.00-
1.70), coronary heart disease (OR: 1.06; 1.00-1.13), mild cognitive impairment (OR: 
2.12; 1.82-2.48), mental and behavioural disorders due to use of alcohol (OR: 1.96; 
1.50-2.57). Use of statin (OR: 0.94; 0.90-0.99) and proton-pump inhibitors (PPI) (OR: 
0.93; 0.90-0.97) were protective for the incidence of dementia. ConClusions: Risk 
factors for dementia found in this study were in line with the literature. There is 
also evidence for a protective effect of statin use with respect to the incidence 
dementia. Further studies are required to investigate the association between PPIs 
and a decreased risk of dementia.
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MODEL fOr rAPiD rELATivE EffECTivENESS ASSESSMENT
Sacareau J1, Tesar T2, D’Andon A1
1HAS (French National Authority for Health), SAINT-DENIS LA PLAINE, France, 2Working group 
for Pharmacoeconomics, Clinical Outcomes and HTA, Slovak Ministry of Health, Bratislava, Slovak 
Republic
oBjeCtives: The objective of EUnetHTA is to strengthen the practical application of 
tools and approaches to cross-border HTA collaboration. Rapid relative effectiveness 
assessments (REAs) are jointly produced, aiming for efficiency gains and applica-
tion in a national context. The 5th REA concerned the assessment of Vorapaxar, 
indicated in the reduction of thrombotic cardiovascular events in patients with 
a history of myocardial infarction. Methods: Assessment was done using the 
HTA Core Model for Rapid REA, developed by EUnetHTA. The project duration was 
10months and consisted of a scoping phase of 4months, followed by an assess-
ment phase of 6months after the positive CHMP opinion. The project was coordi-
nated by The Dutch Healthcare Institute. The main author of the report was French 
national authority for health, with the Ministry of Health of Slovakia as co-author. 
Six other European agencies were involved as reviewers in the different assessment 
steps. The marketing authorization holder (MAH) was provided the opportunity to 
review the report. results: Assessment report included 4 domains: health prob-
lem, description of the technology, clinical effectiveness and safety, and has been 
published on 19/06/2015. Vorapaxar is a selective antagonist of PAR-1 (thrombin 
receptor platelets). The MAH provided TRA 2°P-TIMI 50 trial to evaluate safety and 
efficacy of vorapaxar as an add-on therapy : vorapaxar + ASA ± clopidogrel versus 
ASA ± clopidogrel in subjects with a history of myocardial infarction. The results 
and experiences of the joint assessment will be provided during the ISPOR congress. 
Also we will discuss the extent to which national adaptation of the report takes 
place. ConClusions: HTA agencies have shown that they are able to provide a 
common assessment, using common guidelines, even within the different pro-
cesses and reimbursement systems they are using. The joint assessment process 
is evaluated regularly by the agencies involved. This improves the core model and 
the procedures.
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oBjeCtives: Prior authorization (PA) is a managerial technique frequently imple-
mented to curtail use of expensive drugs and to improve drug-prescribing quality. 
PA requirements may incentivize physicians to document adverse effects (AEs) to 
drugs, sometimes falsely, to meet eligibility-requirements for approval. The objec-
tive of this study was to evaluate the effect of a PA requirement on documentation 
rates of AEs of drugs necessary for approval of more expensive drugs. Methods: 
We conducted a retrospective analysis of physician electronic-reporting behav-
ior of AEs to angiotensin converting enzyme inhibitors (ACE-Is) before and after 
revocation of a PA requirement for angiotensin receptor blockers (ARBs) during 
the years 2004-2013 in an Israeli HMO. Data were stratified by newly treated and 
patients who had been treated for at least one year. The annual rate of AEs to 
ACE-Is in treated patients (number of reported cases of AEs per 1000 ACE-I treated 
patients) was calculated for the five years before and after revocation of the PA 
constraint. results: 151,845 patients met inclusion criteria of the study. AE rates 
amongst newly treated patients peaked to 10.0 cases per 1000 patients during 
2007 gradually falling to 4.6 after the PA requirement was rescinded (P< 0.001). 
Amongst previously treated patients a fall from 5.4/ 1000 to 1.8/1000 patients was 
observed. ConClusions: The PA requirement under investigation was observed 
to be significantly associated with physician propensity for reporting drug side-
effects, possibly erroneously. The decline in incidence of reported of side-effects 
in both subpopulations upon revocation of the PA requirement confirm our sus-
picion that physicians were incentivized to document side effects to ACE-Is to 
meet eligibility-requirements for approval of ARBs. The risk of gaming behavior 
in documentation of drug side effects may increase when side effects cannot be 
substantiated with laboratory tests or diagnostic imaging.
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oBjeCtives: To estimate real-world utilisation of lipid modifying therapy (LMT) 
and low-density lipoprotein cholesterol (LDL-C) goal attainment in the United 
Kingdom. Methods: Individuals with their first and, if present, repeated car-
diovascular (CV) related hospitalisations were identified from 2006-2012 Clinical 
Practice Research Datalink and Hospital Episode Statistics data. Patients > 18 years 
receiving LMT within 180 days before the CV (index) event were followed for 12 
months. Patient cohorts were classified as CV Low/Moderate Risk, CV High Risk, and 
CV Event History. Adherence (medication possession ratio), persistence, switching, 
and therapy augmentation were calculated for statins, ezetimibe and fibrates during 
the follow-up period. Attainment of the recommended LDL-C target of < 1.8 mmol/L 
was assessed for risk groups at the index and 12 months afterward. results: 
Across cohorts, 97% were receiving statins before or at index. Moderate intensity 
statins were used the most. Medication possession ratio ranged from 0.76-0.79 for 
statins, 0.72-0.79 for ezetimibe, and 0.58-0.73 for fibrate users. Persistence at 12 
months was 51%-52% for statin, 40%-50% for ezetimibe, and 36%-45% for fibrate 
users. Approximately 2% of statin users switched to new medications, compared 
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and daily activities (placebo, –0.0001 [–0.002, 0.002], P= 0.9; LDX relative to placebo, 
0.0006 [–0.002, 0.003], P= 0.6) or after adjusting for BE days/week, functionality, and 
impairment in work and daily activities (placebo, –0.0008 [–0.003, 0.002], P= 0.5; LDX 
relative to placebo, 0.0002 [–0.002, 0.003], P= 0.9). ConClusions: The positive effect 
of LDX on HRQoL/patient utlility is indirect and mediated in part by LDX effects on 
BE frequency and disability/functioning.
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oBjeCtives: To evaluate the effect of lisdexamfetamine dimesylate (LDX) and 
changes in binge eating (BE) days/week and BE episodes/week on disability in 
patients with protocol-defined moderate to severe binge eating disorder (BED) over 
12 weeks. Methods: In two identically designed, 12-week, double-blind, placebo 
(PBO)-controlled trials, adults meeting DSM-IV-TR BED criteria were randomized 
(study 1, N= 383; study 2, N= 390) to PBO or LDX (50 or 70 mg). LDX was statistically 
superior to PBO in reducing the number of BE days/week (the primary endpoint) 
and showed numerical improvements in BE episodes/week (a secondary endpoint). 
The trials assessed disability with Sheehan Disability Scale (SDS) as an explora-
tory endpoint. Observations corresponding to visits from baseline to week 12 were 
analyzed; data were pooled across studies. The current post hoc analyses were 
performed using mixed-effect logistic regression models to determine the relation-
ship between: (1) LDX therapy and disability, and (2) BE days/week and disability, 
and BE episodes/week and disability. P-values are unadjusted and presented for 
descriptive purposes only. results: LDX therapy showed a numeric improvement 
on disability as measured by SDS. The odds ratio (OR)/week for disability (> 0 score) 
measured by SDS total score for LDX relative to placebo was 0.70 (P≤ 0.001). Higher 
BE frequency counteracted the improvement in disability which was significant 
in the lowest tertile of BE frequency (tertile 3). ORs/week for disability (> 0 score) 
measured by SDS total score in BE days/week tertiles 1, 2 and 3 (relative to tertile 1) 
were 0.66, 1.37 and 1.72, and in BE episodes/week 0.66, 1.44 and 1.69, respectively (all 
P≤ 0.001). ConClusions: Findings of this longitudinal analysis indicate that LDX 
therapy has a positive effect on disability, as measured by SDS, of BED patients. The 
analysis also showed that reduction in both BE days/week and BE episodes/week is 
associated with improvement in disability over 12 weeks.
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oBjeCtives: Treatment continuation of four long acting, injectable, antipsychotic 
drugs: paliperidone palmitate, risperidone microspheres, olanzapine pamoate and 
haloperidol decanoate, was evaluated in the Dutch outpatient setting using panel 
data from public pharmacies. Restart rates, maintenance dose distribution, age dis-
tribution and frequency of co-prescriptions were also investigated. Methods: The 
IMS LifelinkTM Treatment Dynamics database was used, applying appropriate selec-
tion criteria. Four patient cohorts that started paliperidone palmitate, risperidone 
microspheres, olanzapine pamoate or haloperidol decanoate treatment, between 
1 April 2011 and 31 March 2012, and 1 October 2012 and 31 September 2013 were 
analyzed. All cohorts included at least 13 months of follow up. Treatment continua-
tion was investigated. results: After 180 days, in both study periods, a significantly 
higher percentage of patients continued treatment with paliperidone palmitate. 
After six months, respectively 59% and 55% of patients continued paliperidone pal-
mitate. For risperidone microspheres this was 42% and 40%, for olanzapine pamoate 
25% and 43%, and for haloperidol decanoate 42% and 47%. In both study periods, sig-
nificantly higher percentages of patients restarted index treatment within 3 months 
when using paliperidone palmitate (42% and 40%) or olanzapine pamoate (44% and 
42%) compared to risperidone microspheres (35% and 33%) or haloperidol decanoate 
(26% and 28%). For all therapies, dosing was comparable between treatment initia-
tion and discontinuation. Medication used to treat extrapyramidal symptoms was 
on average more frequently used with haloperidol decanoate (24% and 18%) than 
with paliperidone palmitate (4% and 5%) risperidone microspheres (11% and 3%), or 
olanzapine pamoate (0 and 6%). ConClusions: Results of the database research 
indicate that a higher percentage of patients treated with paliperidone palmitate 
continued therapy and restarted therapy than patients receiving the other three 
long-acting antipsychotics. Co-medication against extrapyramidal symptoms was 
more frequently used with haloperidol decanoate. FINANCIAL SUPPORT: This work 
was funded by Janssen.
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oBjeCtives: Dementia is known as a major public health problem affecting both 
patients and caregivers, and placing a high financial strain upon society. In com-
munity-dwelling patients, it is important to support informal caregivers in order 
to help them sustain their demanding role. Previous reviews about effectiveness 
of such supporting strategies often included a small number of studies, focused 
oBjeCtives: Major Depressive Disorder (MDD) may significantly affect cognitive 
domains of attention, concentration and memory. While the burden of cogni-
tive dysfunction in Schizophrenia is well established, the investigation of cogni-
tive impairment in Bipolar Disorder (BD) and MDD has attracted the interest of 
research only more recently. Therefore, it is of great interest to understand cli-
nician’s perception about cognitive dysfunction in MDD and to raise awareness 
about this issue. Methods: Between December 2014 and January 2015, 128 Italian 
psychiatrists were recruited to participate to an on-line survey whose aim was 
to understand psychiatrists’ perception about cognitive symptoms in MDD. The 
questionnaire comprised three sections: the first investigating psychiatrists’ socio-
demographic and professional profile, the second assessing cognitive symptoms rel-
evance without mentioning they represented the study focus and the third explicitly 
investigating cognitive symptoms. results: Cognitive symptoms were considered 
a relevant dimension of MDD and they appeared amongst the most frequently 
cited residual symptoms compromising patients’ work and influencing relapse risk. 
About 70% of psychiatrists declared that cognitive symptoms significantly influ-
ence the antidepressant choice. However, in the previous questionnaire section 
where focus on cognitive symptoms was not revealed yet, cognitive symptoms 
appeared less frequently considered for antidepressant choice. ConClusions: 
Study results revealed a clear understanding of cognitive symptoms relevance in 
MDD. Nevertheless, the discrepancy between psychiatrists’ perception and their 
therapeutical choices underlines the presence of an unmet need that should be 
addressed increasing the awareness about the positive effects on cognitive symp-
toms of existing drugs, which could allow a more symptom-oriented therapeutical 
intervention.
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oBjeCtives: Ketamine has demonstrated rapid and robust antidepressant effects 
in patients with treatment resistant depression (TRD) in investigational clinical 
trials. The objective of this study was to compare the efficacy of ketamine with 
other pharmacological and somatic treatments in adult TRD patients. Methods: 
A systematic literature review was performed in September 2014, using a predefined 
search strategy including MEDLINE, EMBASE and the Cochrane Library. TRD was 
defined as ≥ 2 antidepressant treatment failures. Thirty-one randomized controlled 
trials (RCTs) were included: 19 RCTs investigating 13 pharmacological interven-
tions and 12 RCTs investigating electroconvulsive therapy (ECT) or repetitive tran-
scranial magnetic stimulation (rTMS). Key outcomes were: disease severity change 
from baseline at 2 weeks measured on the Montgomery–Åsberg Depression Rating 
Scale (MADRS) and response rate at 2 weeks (i.e. reduction of ≥ 50% in MADRS total 
score). Placebo and sham arms were pooled into one reference group.The evidence 
base was synthesised by means of a Bayesian network meta-analysis. results: 
Ketamine seemed more efficacious in reducing depressive symptoms at 2 weeks 
than aripiprazole augmentation (mean difference in MADRS reduction -11.0; 95% 
Credible Interval [CrI] -17.8 to -4.1), venlafaxine monotherapy(-12.7; [-23.2 to -2.2]), 
olanzapine/fluoxetine combination (-12.5; [-24.9 to -0.2]), fluoxetine monotherapy 
(-12.5; [-24.4 to -0.6]), quetiapine augmentation (-11.6; [-20 to -3.1]), nortriptyline 
monotherapy (-13; [-25.7 to -0.3]), lamotrigine augmentation (-13.2; [-24.2 to -2.2]), 
ECT (-9.4; [-18.4 to -0.5]) and rTMS (-9.8; [-16.2 to -3.5]). Also, ketamine showed the 
highest probability of being the best treatment (57%). The % responders at 2 weeks 
was 5-fold higher for ketamine than for aripiprazole (odds ratio (OR) 5.2; 95% CrI 
[1.4-27.5]) and rTMS (4.8; [1.1-27.5]), and 14-fold higher compared to placebo/sham 
treatment (13.7; [3.8-69.1]). ConClusions: Based on the evidence synthesis of 
available RCTs investigating the efficacy of TRD treatments at 2 weeks, ketamine 
demonstrated superior efficacy compared with other pharmacological and somatic 
interventions.
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oBjeCtives: To evaluate the effects of lisdexamfetamine dimesylate (LDX) on 
changes in health-related quality of life (HRQoL) in individuals with protocol-
defined moderate to severe binge eating disorder (BED). Methods: In 2 identically 
designed 12-week, double-blind, placebo-controlled trials, adults with protocol-
defined moderate to severe binge eating (BE) who met DSM-IV-TR BED criteria were 
randomized (study 1, N= 383; study 2, N= 390) to placebo or LDX (50 or 70 mg). HRQoL 
was assessed at baseline and treatment weeks 4, 6, 8, 10, and 12/early termination 
using the EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L; a prespecified 
secondary endpoint). For this post hoc analysis, participant EQ-5D-5L profiles were 
converted to utility index scores (range: –0.109 [worst state] to 1 [best state]) and 
pooled across studies. Unadjusted and adjusted random effect tobit regressions 
were conducted to examine the longitudinal relationship between LDX treatment 
and HRQoL. results: Mean ± SD EQ-5D-5L index scores in the pooled treatment 
groups were 0.877±0.105 for placebo (n= 358 observations) and 0.882±0.118 for LDX 
(n= 364 observations) at baseline and 0.909±0.115 for placebo (n= 296 observations) 
and 0.933±0.102 for LDX (n= 302 observations) at week 12. Mean (95% CI) improve-
ment/week in EQ-5D-5L index scores without adjustment was statistically sig-
nificant for placebo (0.0059 [0.005, 0.007]; P< 0.001) and for LDX relative to placebo 
(0.0032 [0.001, 0.005]; P= 0.001). Treatment effects on HRQoL were no longer signifi-
cant after adjusting for BE episodes/week, functionality, and impairment in work 
